Midline glioma MRI AI model: preoperative molecular subtyping and prognosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter prospective observational study validating an AI model that uses preoperative MRI and basic patient info to predict H3K27M, IDH, and 1p/19q status. The model also estimates prognosis to support clinical decisions. Accuracy will be measured against postoperative pathology using metrics like sensitivity, specificity, accuracy, F1, and AUC, with time-dependent AUC for survival prediction. Exploratory analyses will assess potential impact on preoperative treatment planning and risk stratification.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with diffuse gliomas were pathologically and molecularly diagnosed.
* The clinical case data of all patients were complete.
* Patients underwent preoperative MRI examination.

Exclusion Criteria:

* The tumor is not located in the intracranial midline.
* Cases in which MRI were incomplete or with significant noise and artifacts.

Where it's running

• Xiangya Hospital of Central South University
  Changsha, Hunan, China Recruiting

Study contacts

• Study coordinator: Gong Xuan, MD.
• Email: gong.xuan@csu.edu.cn
• Phone: 0086-731-8975-3037

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PET-guided surgery for high-grade glioma

  This project will try using 18F-DOPA PET to guide surgeons to remove tumor beyond MRI-visible areas in adults with high-grade glioma to see if it delays progression and extends survival.

  Recruiting at 2 sites Universita degli Studi di Genova · Torino, Turin and 1 other locations · NCT07567196

• AI-assisted diagnosis for malignant brain tumors

  This project will test an AI system that uses routine preoperative MRI scans to automatically segment and classify malignant brain tumors in adults to help guide diagnosis and care.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang and 1 other locations · NCT07198256

• HMPL-306 treatment for gliomas with IDH1 or IDH2 mutations.

  This study will test whether HMPL-306, a drug that blocks mutant IDH1 and IDH2, is safe and shows early benefit in adults with IDH‑mutant gliomas.

  Recruiting Phase 1 Hutchmed · Shanghai, Shanghai Municipality · NCT07025018

• Testing TNG456 and Abemaciclib in Patients with Solid Tumors Lacking MTAP

  This study is testing a new drug called TNG456, alone and with another drug called abemaciclib, to see if it helps people with advanced solid tumors that have lost a specific gene called MTAP.

  Recruiting at 15 sites Phase 1/2 Tango Therapeutics, Inc. · Scottsdale, Arizona and 14 other locations · NCT06810544

• Measuring fluorescence from surgical suction during glioma surgery

  This study is testing a new device that measures fluorescence from surgical suction during glioma surgery to see if it helps doctors remove more tumor tissue compared to what they can see with their regular tools.

  Recruiting Kuopio University Hospital · Kuopio, Kuopio · NCT06736470

• Injection of natural killer cells for treating gliomas

  This study is testing whether a new treatment using natural killer cells can help young patients with high-grade gliomas, like glioblastoma, fight their cancer better.

  Recruiting Phase 2 Kian Immune Cell Company · Tehran · NCT06687681

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.